ATUM Appoints Industry Veteran Gavin Barnard, Ph.D., as Chief Scientific Officer
As CSO,
- Hit-to-Lead Services: increasing drug candidate assessment by in silico modelling, small scale expression with developability analytics and AI-guided sequence optimization.
- Cell Line Development: maintaining the growth of ATUM's Leap-In Transposase technology, with over 50 INDs now filed.
- Complex Modalities Roadmap: further enhancing ATUM's service offerings in support of more complex modalities such as multispecifics and ADCs.
"I am delighted to welcome Gavin to ATUM," said
"I have seen firsthand the transformative power of ATUM's technology to solve the industry's most pressing bottlenecks," said
About ATUM
ATUM is a fully integrated biotechnology contract research organization that provides services for gene design, protein engineering, and cell line development. By combining machine learning, synthetic biology, and proprietary expression technologies, ATUM helps partners worldwide transform digital sequences into clinical reality. ATUM is headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/atum-appoints-industry-veteran-gavin-barnard-phd-as-chief-scientific-officer-302743989.html
SOURCE ATUM
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parksy (parksy.com) Mapped Parking Around 12 of America's Biggest Venues: Nearly 2,000 Options Near Madison Square Garden, 18 Near Hard Rock Stadium
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Missed Bitcoin and XRP’s Early Gains? Apeing Could Be the Next Big Crypto Before the Crowd Arrives – Presale Coming Soon
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share